Please login to the form below
trial failures
This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.
Merck gets first approval for MET inhibitor tepotinib in Japan
combination. MET is known as a resistance mechanism for EGFR-positive NSCLC, and Merck also has a trial on the go of tepotinib plus Tagrisso in this setting. ... ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of
Latest news
-
Northsea Therapeutics raises $40m to develop fish oil NASH drug
Looking for mid-stage trial success in field littered with failures. Following in Amarin’s footsteps, Dutch biotech Northsea Therapeutics has successfully raised $40m (36m) for the development of a fish ... French pharma Genfit also has a candidate
-
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer
The data from the phase 3 JAVELIN Bladder 100 trial has confirmed that Bavencio statistically improves survival in its approved patient population. ... The extension into the earlier indication in bladder cancer is vital for Bavencio, which has been
-
New efficacy data boosts Aimovig’s migraine market lead
Data from the active treatment phase of STRIVE looked at efficacy and safety of Aimovig (70 and 140 mg) in episodic migraine patients with prior preventive treatment failures. ... Trial data shows that 55% of patients on Aimovig 140 mg experienced at
-
Merck bulks up in cancer with $2.2bn Peloton buy
The biotech’s first phase 2 trial recruited patients with VHL mutations and is testing PT2977 as a monotherapy, while a second all-comer metastatic RCC trial is pairing the drug ... which has recently seen some late-stage trial failures involving
-
Realm toppled by second mid-stage trial flop
PR022 did not show the desired effect in this trial,” said Alex Martin, the biotech’s CEO. ... considerably after the twin trial failures.
Northsea Therapeutics raises $40m to develop fish oil NASH drug
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer
New efficacy data boosts Aimovig’s migraine market lead
Merck bulks up in cancer with $2.2bn Peloton buy
Realm toppled by second mid-stage trial flop
More from news
Approximately 5 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
And the timing couldn’t be more auspicious because, after more than two decades of clinical trial failures, there’s good reason to believe we’ll finally see a light at ... However, because of the less advanced trial methodologies used at that point,
-
Interview: AstraZeneca's Susan Galbraith
major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.
-
An eye towards the biobetter in South Korea
Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. ... Some companies already have their biobetter pipelines in clinical trial stage.
Alzheimer’s: the search for a cure
Interview: AstraZeneca's Susan Galbraith
An eye towards the biobetter in South Korea
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
AstraZeneca hires Roche’s Pascal Soriot as CEO
a series of clinical trial failures leading to the departure of AZ's previous CEO Brennan in April, 2012.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Alzheimer’s disease: reviewing the immediate treatment horizon
However, the learnings from these ‘failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years. ... A recent article by BLH Consultant David Cooney explored the bleak
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Rocky start for Biogen’s Alzheimer’s drug Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- US demand for COVID-19 antibody treatments rising fast
- Our mission: helping patients in areas of unmet medical need
- Novo Nordisk settles US insulin pricing dispute for $100m
- Mysterious big pharma company eyes US biotech Acceleron
- COVID-19 changed change and communications will never be the same
- Understanding behaviour change: A Porterhouse Insights specialism
- Lynparza significantly delays disease progression as first-line treatment in prostate cancer
- David Hunt launches independent agency The Considered
- Live Webinar: Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Lucid Group celebrates a double win at Communiqué 2021
- China backs use of Roche’s Actemra for coronavirus
- Future of MHRA uncertain amid Brexit-fuelled shake up
PMHub
certain health
Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...
Latest intelligence
- Understanding behaviour change: A Porterhouse Insights specialism
- ...
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
